background: Breast cancer during pregnancy is often more advanced than in non-pregnant women. Nevertheless, no case of metastasis inside the placenta has been reported. Previously, we showed that placental-explants eliminated breast cancer cells from their surroundings, due to cell-death and elevated migration. Our objective was to find the underlying mechanisms of these phenomena. methods and results: Our model contained Michigan Cancer Foundation 7 (MCF7) or T47D cells co-cultured with and without human placental explants. Microarray analysis, validated by quantitative PCR, of MCF7 following their placental co-culture suggested activation of estrogen (E 2 ) signaling. As extensive cross-talk exists between E 2 and progesterone, their involvement in mediating placental effects on breast cancer cells was tested. Indeed, addition of E 2 and progesterone receptor (ER and PR) inhibitors to the co-culture system reduced cancer cell motility, yet did not alter cell-cycle or death. E 2 and progesterone concentrations in placental media were found to be similar to those of early pregnancy blood levels. Interestingly, placental-breast cancer co-culture media contained lower progesterone (P , 0.05) and higher E 2 (200%, P , 0.05) levels than placentae cultured separately. Placental supernatant and E 2 and progesterone at placental levels were sufficient to increase MCF7 and T47D migration and invasion (P , 0.05), yet did not alter MCF7 cell-cycle or death. Furthermore, placental supernatant elevated p38 and Jun N-terminal kinase (JNK) phosphorylation in both cell lines (P , 0.05). Inhibitors of JNK, ER and PR reversed MCF7 and T47D motility induced by the placenta, suggesting their involvement.
Introduction
Breast cancer is one of the most common malignancies in pregnant women (Antonelli et al., 1996; Pavlidis, 2002; Smith et al., 2003; Jacobs et al., 2004; Pereg et al., 2008; Lyons et al., 2009) . Numerous publications have shown that pregnant women diagnosed with breast cancer develop larger tumors and are more likely to develop metastases (Shousha, 2000; Woo et al., 2003; Pereg et al., 2008) . These observations suggest that pregnancy may alter the prognosis of breast cancer. A possible cause may be the 2006). Its levels can be regulated by estrogen (E 2 ) (Smyth et al., 1988; Duong et al., 2007) . Furthermore, extensive cross talk exists between E 2 and progesterone. Progesterone reduces ERa levels and has some anti-estrogenic effects, whereas the opposite is evident regarding the effect of E 2 on the progesterone receptor (PR) (Velarde et al., 2007; Sukocheva et al., 2009) . A major concern is the possible effect of the malignancy on the fetus. Although the placental intervillous space is characterized by a slow flow of generous blood volumes in a large surface area, which creates an ideal biologic environment for metastasis initiation (Jackisch et al., 2003) , metastasis to the placenta or embryo is rare (Jackisch et al., 2003) . The limited number of metastases found on the placenta suggests that there are unknown placental factors that hinder cancer cell growth in its close proximity. In fact, less than 100 cases of maternal tumors metastasizing to the placenta or fetus have been reported since 1866 (Alexander et al., 2003; Al-Adnani et al., 2007; Shuhaila et al., 2008; Pages et al., 2010; Thelmo et al., 2010) . If breast cancer is a rather common malignancy during pregnancy and usually diagnosed at advanced stages, it is surprising that no cases of fetal or villous invasion in these patients have ever been reported. Thus, this suggests that the placenta serves as a non-supportive microenvironment for malignant cells in general, and especially for breast cancer cells.
During placental implantation, extravillous trophoblast (EVT) cells invade the uterus, replace vessel endothelium and are eventually stationed at the placenta front line, facing the metastatic invasion, which suggests their involvement in metastatic inhibition.
In our previous study, we investigated the unique effect of the placenta on breast cancer cells. We have established a biological model in which human first trimester placental explants were co-cultured with Michigan Cancer Foundation (MCF7) or T47D cells on a 'Matrigel' substrate (Tartakover-Matalon et al., 2010) . MCF7 and T47D cells are commonly used as a breast cancer cell model to study E 2 and progesterone signaling, as they express ERa (Bourdeau et al., 2008) and PR (Sukocheva et al., 2009) . Our study has shown that the placenta enhanced MCF7 cell death. Moreover, it led to the formation of uniquely shaped breast cancer cell aggregates, and eliminated the MCF7 and T47D cancer cells from its proximity. Interestingly, breast cancer cells were most significantly affected in the areas of EVT cell differentiation (Tartakover-Matalon et al., 2010) , suggesting that EVT cells or their invasion process could be a possible cause for these phenomena. In the current study, we aimed to establish mechanisms that would explain the earlier-mentioned observations.
First, we performed a microarray analysis of MCF7 cells preexposed to placental explants.
Manipulations of the breast cancer E 2 pathway (demonstrated below) were shown using pathway analysis. On the basis of these results and taking into account the significance of hormones during pregnancy, we focused on E 2 and progesterone involvement in mediating placental effects on MCF7 and T47D cells. In addition, we tested the involvement of these two hormones in the placental culture system by using specific ER and PR inhibitors.
This study provides an insight to the effect of pregnancy on cancer cell behavior, and suggests mechanisms underlying the placental defense against breast cancer metastasis.
Materials and Methods
Cell culture T47D (kindly provided by Dr Ilan Tzarfati, Tel Aviv University) and MCF7 breast cancer cell lines (BCCL) [with and without enhanced green fluorescent protein (eGFP) tags] were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), L-glutamine (2 mM) and Pen-Strep-Nystatin antibiotics (Biological Industries, Israel). Cells were maintained in 5% CO 2 at 378C. Cells tagged with eGFP were supplemented with 300 mg/ml neomycin (G418 sulfate, Invivogen, San Diego, CA, USA).
Transfection
Commercial vectors eGFP-C1 (Clontech, Mountain View, CA, USA) were characterized with eGFP and neomycin (G418)-resistant genes. Three microlitres of FuGENE six transfection reagent (Roche Diagnostics, Mannheim, Germany) was added to 97 ml of OPTIMEM I (5 min, room temperature, GIBCO, USA) and 1 mg of plasmid DNA was added (45 min, room temperature). The entire volume (100 ml) was added to 10 5 MCF7 or T47D cells previously seeded in a 24-well plate. For selecting eGFP positive cells, cells were exposed to 300 mg/ml neomycin. Fluorescence was analyzed by fluorescence-activated cell sorter (FACS; Navios, Beckman Coulter, Miami, FL, USA).
Placental tissue preparation and co-culture
Culture techniques were based on previously described methods (Genbacev et al., 1992 . Placentae at 6 -9 weeks of gestation were retrieved from normal pregnancies terminated for psychosocial reasons. The study was approved by the ethics committee of Meir Medical Center. Placental villi of 10 mg wet weight were transferred into culture inserts (Millipore, Carrigtwohill Co., Cork, Ireland) previously layered with 'Matrigel' (BD Biosciences, Bedford, MA, USA) and placed into 24-well plates. After 1.5 h, 700 ml of medium (DMEM/ F-12, HAM), L-glutamine (2 mM), sodium pyruvate (1 mM), HEPES (25 mM), antibiotics and 10% FCS (Biological Industries, Beit Haemek, Israel) were added to the bottom of the culture dish and left overnight. After 12-16 h, 4 × 10 4 of T47D-eGFP or MCF7-eGFP cells with or without inhibitors were added. Breast cancer cells plated alone on 'Matrigel' served as controls. After 24 h, a bare area assay (See below) was performed, culture media were collected, replaced and stored at 2808C. The bottom well medium was also replaced. Following 60 h co-culture, the bare assay was performed again, media were collected and cells were retrieved by trypsin-EDTA (Biological Industries) from the 'Matrigel' and processed in one of the following ways:
(1) MCF7-eGFP/T47D-eGFP were sorted out by FACS (BD FACS Aria, Tel Aviv University). Following sorting, protein and RNA extractions were performed. (2) MCF7-eGFP were analyzed by FACS (Navios, Beckman Coulter, USA), while 'gating in' only eGFP positive cells.
Placenta samples from different patients were used in each experiment.
Hormone level analysis
Progesterone and E 2 levels were measured by Immulite 2000 analyzer (Endocrinology Laboratory, Meir Medical Center). The analysis was done using solid phase (bead) competitive chemiluminescent enzyme immunoassay kits L2KPW2 and L2KE22, respectively, according to the manufacturer's instructions. Medium placed on 'Matrigel' for the same time provided the background value. In the experiments, three sources of placental supernatant were used: the first was collected from a single placenta, while the second and the third were pooled media from 5 or 6 placentae.
Inhibitors
Hormone receptor inhibitors Fulvestrant (ICI 182 780) and Mifepristone (RU486) (both purchased from Sigma Aldrich, USA) were diluted in EtOH to 100 and 10 nM, respectively. The same volume of EtOH served as control.
Mitogen-activated protein kinase (MAPK) inhibitors SB 202190 (p38 MAPK inhibitor) and SP600125 inhibitor) [Jun N-terminal kinase (JNK) were dissolved in dimethylsulfoxide (DMSO)] at 20 mM (SIGMA and Biomol Int., USA, respectively). MCF7 and T47D cells were exposed to inhibitors for 1 h prior to assays.
Visual assessment of MCF7 and T47D distribution (bare area assay)
Placental explant co-cultures were examined daily under a microscope (Olympus IX71). To assess bare areas around the placenta and EVT cell differentiation and invasion, each placental explant was divided into 12 sectors (like a clock). The number of sites from which MCF7-eGFP or T47D cells disappeared was calculated. (For example, nine sectors were considered as 75% effect (9/12 × 100 ¼ 75%, Fig. 1 ). The effect of ER and PR inhibitors on bare area size was analyzed by comparing the size of the bare areas formed with and without the inhibitors. EVT cell migration from the placenta to the 'Matrigel' can be identified by microscopic observation as finger-like outgrowth projections that surround the placental explants and are located very close to the villous area/surface . As breast cancer cells migrate further than EVT, areas almost empty of cells were created that could be easily distinguished from areas that contained breast cancer cells. In addition, the eGFP tag in the breast cancer cells was used to differentiate between them and the EVT cells that lack the eGFP tag.
Cell-cycle analysis
This was done as described by Chu et al. (1999) . Briefly, retrieved cells were washed with phosphate-buffered saline (PBS), and fixed with 0.5% formaldehyde (Gadot, Israel) and 0.1% sodium azide (Sigma Aldrich, St Louis, MO, USA; 1 h, 48C). Fixation was followed by cell perforation (70% EtOH in PBS, overnight, 208C). The next day, cells were exposed to 40 mg/ml propidium iodide (PI) (Sigma Aldrich) and 100 mg/ml ribonuclease A (Sigma Aldrich) in PBS (30 min, room temperature, in the dark). Cell DNA content was analyzed using FACS (Navios, Beckman Coulter, USA). In co-culture experiments, only MCF7-eGFP-gated cells were tested. Results were analyzed using ModFit LT 3.0 (Verity Software House, ME, USA).
Assessment of apoptosis and necrosis
Annexin V-Alexa Fluor 680 (AF680; Invitrogen, Carlsbad, CA, USA) supplemented with 10 mg/ml PI (Sigma Aldrich) was used to detect cell death according to the manufacturer's instructions and assayed for fluorescence by FACS (Navios, Beckman Coulter, Fullerton, CA, USA). In co-culture experiments, only MCF7-eGFP-gated cells were analyzed. For other systems that did not require the eGFP tag, we used Annexin V-PE (BioVision, Mountain View, CA, USA) supplemented with 0.1 mg 7-aminoactinomycin D (7AAD) (eBioscience, San Diego, CA, USA). Annexin V+/PI-(or Annexin V+/7AAD-) cells were considered apoptotic and Annexin V+/PI+ (or Annexin V+/7AAD+) cells were designated late apoptotic/necrotic. All results are expressed as the percent of total cell number.
Gelatin zymography
Media (20 ml) were electrophoresed at non-reducing conditions in 10% polyacrylamide gel containing 1 mg/ml gelatin type A (Sigma Aldrich). Gels were washed in 2.5% Triton X-100 and incubated overnight in 50 mM Tris -HCl (pH 7.5) and 5 mM CaCl 2 . Coomassie blue staining followed by destaining [20% methanol, 7% acetic acid in double distilled water (DDW)] allowed visualization of clear lysis zones against the blue background. matrix metalloproteinases 2 and 9 (MMP2 and 9) were identified by a marker and by the migration of gelatinase zymogram standard (Chemicon, Temecula, CA, USA) for human MMP2 and MMP9 that were electrophoresed adjacent to the tested aliquot. Optical densities of clear zones were measured as arbitrary units by using LAS3000 Image reader (Fugifilm, Greenwood, SC, USA). Results were normalized to background values using the Multi-gauge V3.0 program (Fugifilm, Greenwood, SC, USA). Proactive bands were strong, whereas active forms were very weak and could not be separately evaluated.
Scratch test assay
Confluent MCF7 or T47D cell monolayers were wounded by pipette tip. Following wounding, placental or breast cancer cell (MCF7 or T47D) supernatant or E 2 + progesterone with/without inhibitors was added to the cells. Wound closure was monitored by microscopy at 24 h 
Transwell invasion assay
Invasion assays were done using Transwell plates (Costar, Corning, NY, USA) based on methods previously described (Shaw, 2005) . The upper chamber of each well was coated with 40 ml 'Matrigel' (0.125 mg/ml) and left to dry overnight at 378C. Dilution of 'Matrigel' was done using placental/BCCL supernatant. Then, wells were rehydrated with 40 ml of DMEM for 1 h, and 10 5 MCF7 or T47D cells were added. The lower chamber was filled with 600 ml media (10% FCS) supplemented with 5 mg/ml fibronectin (Sigma Aldrich). Plates were incubated at 378C for 48 h. Non-invading cells from the upper chamber were removed using cotton swabs. Inserts were stained with Accustain (Sigma Aldrich, Steinheim, Germany) for 30 min. Invading cells were counted using an inverted microscope.
RNA extraction and RT cDNA synthesis MCF7 or MCF7-eGFP cells were washed with PBS, and RNA was extracted using RNeasy kit (QAIGEN, Valencia, CA, USA) according to the manufacturer's instructions. RNA concentrations were measured at 260/280 nm using Nanodrop-1000 (Thermo Scientific, Wilmington, DE, USA). Extracted RNA was converted to cDNA using Applied Biosystems kit according to the manufacturer's instructions.
Real-time quantitative PCR
Specific primers were designed according to 'Primer Express 3.0' software specifications. Quantitative PCR (qPCR) reactions were done using Power SYBR Green (Applied Biosystems, Warrington, UK) according to the manufacturer's instructions. The following genes were tested: Id1, KLF9, ESR1, GREB1, MUC1 and PGR (Primers are listed in Table I ). RPL18A housekeeping gene served as the control. Primers were normalized by specific cDNA standard curves obtained from known amounts of cDNA (primers were purchased from Hylabs, Rehovot, Israel).
Western blotting
MCF7, T47D, MCF7-eGFP or T47D-eGFP cells were washed with PBS and lysed in buffer (50 mM HEPES, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 50 mM NaF, 10 mM NaPPi, 2 mM NaVO3, 10 mM EDTA, 2 mM EGTA, 1 mM phenylmethylsulphonyl fluoride and 10 mg/ml leupeptin) on ice for 10 min. Protein lysate from 2 -3 × 10 5 cells was mixed (1:5) with loading buffer, denatured for 10 min at 658C and separated on SDS -PAGE and transferred to a polyvinylidene difluoride membrane. After blocking (5% dry milk in tris-buffered saline-T), membranes were incubated at 48C overnight with primary antibodies (Supplementary data, Table SII ). Bound antibodies were visualized using peroxidase-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) followed by enhanced chemiluminescence detection (Pierce, Rockford, IL, USA). Optical densities were visualized and measured as arbitrary units by LAS3000 Imager (Fugifilm, Greenwood, SC, USA). Results were normalized to Tubulin using Multi-gauge V3.0 program (Fugifilm).
Microarray performance and bioinformatics analysis
Affymetrix GeneChip w Human Affymetrix GeneChip w Human Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA) were used for gene expression analysis according to the instruction manual http://media.affymetrix .com/support/technical/datasheets/gene_1_0_st_datasheet.pdf). Microarray expression profiles were extracted from raw CEL files using Partek Genomic Suite (Partek w software, version 6.4 Copyright
Inc., St. Louis, MO, USA; www.partek.com). Data were normalized and summarized with the robust multi-average algorithm to allow for data comparison across the different arrays (Irizarry et al., 2003) followed by one-way analysis of variance. Genes were identified as differentially expressed with a cut-off of P , 0.05 and 1.25-fold expression difference). Gene ontology (GO) functional classification and pathway enrichment analysis of differentially expressed genes was assessed by the following tools: 
Statistical analysis
Paired Student's t tests were used to test differences between treatments. An effect was considered significant when the P-value was ≤ 0.05. Interaction between treatments was assessed according to the following formula:
where P(A) denotes placental hormones; P(B) BCCL hormones; P(A + B) co-culture hormones; q , 0.85 was considered antagonistic interaction; q . 1.15 was considered a synergistic interaction; 1.15 .q . 0.85 was interpreted as an additive interaction.
All the experiments were repeated a minimum of three times. 
Results

Microarray analysis demonstrated modulation of the ER signaling pathway in MCF7 cells co-cultured with placental explants
Placental explants secrete various cytokines and growth factors that may alter diverse MCF7 pathways. In order to study gene expression in MCF7 cells following co-culture, a whole human genome cDNA microarray analysis was done. MCF7-eGFP cells were cultured with and without placental explants (n ¼ 3), purified by FACS and their total RNA was extracted. RNA was hybridized to GeneChip Human Gene 1.0 ST array kit (Affymetrix), and analyzed as described in Materials and Methods. Seven-hundred and eight genes were differentially expressed (fold change cut off .1.25 and P , 0.05) between MCF7-eGFP cells co-cultured with placental explants and control MCF7-eGFP cells cultured alone. GO comparative analysis between this gene set (708 genes) and previously published gene sets using Toppgene and GESA softwares revealed two major categories of significant similarities. The first category includes genes that deal with the effect of anti-estrogens and estrogen on breast cancer cells, as well as with the acquired endocrine therapy resistance (to anti-estrogen) (Table II, 2, [5] [6] [7] [8] [9] 12) . The second category was enriched with genes that are changed in breast cancer cells as a result of ER downregulation (Table II, 1, 3 -4, 10-11) . Functional analysis of these genes with Toppgene software (using FDR correction, P , 0.05) highlighted 'Breast_cancer_estrogen_signaling' as one of the most significantly changed pathways (Table II, 13, gene list at Supplementary data,  Table SI ). Most E 2 responsive genes were up-regulated following placental co-culture (MUC1, C3, SLC7A5, GREB1, PGR, TGFA and CD44). Whereas expression of ESR1 and CLU that are known to be downregulated by E 2 was reduced (Heikaus et al., 2002; Stoica et al., 2003) , as were the remaining three E 2 responsive genes (STC2, GSN and THBS1; Supplementary data, Table SI ). Significant changes were also observed in the 'androgen/estrogen/progesterone biosynthesis pathway' and the 'steroid biosynthesis pathway' in the MCF7 cells co-cultured with the placenta (Toppgene and Genecodies 2, respectively, Table II , 14-15 and Supplementary data, Table SI ). Participation of the indicated pathways is attributed to a significant decrease in the LIPA and SOAT1 enzymes and an elevation in the CYP27B1 enzyme. LIPA and SOAT1 are known to be repressed by E 2 (Tomita et al., 1996; Snyder et al., 2009) , whereas CYP27B1 enzyme is known to be induced by E 2 in MCF7 cells (Lechner et al., 2006 Placental hormones and breast cancer cell migration drugs with the highest probability of interacting with our gene set (708-gene set, Table II , 16-18). These three drugs modulate E 2 signaling: genistein is an isoflavonoid that can bind to ER and may function as selective estrogen receptor modulators, diethylstilbestrol is a synthetic non-steroidal estrogen and progesterone is known to oppose ER-mediated gene-regulatory events (Graham and Clarke, 1997) . Nevertheless, the promoter region analysis of the 708 genes did provide evidence of enrichment in the estrogen response elements motif (ERE motif). Bourdeau et al. (2008) , who previously characterized the gene regulation in MCF7 cells by E 2 , found that the EREs sequences were enriched only in up-regulated genes. Indeed, we found an enrichment in the ERE motif in the up-regulated genes (V$ER_Q6_01 (GeneCodis2, Toppgene) and V$ER_Q6_02 (GeneCodis2), Table II , 19-21) .
Validation of microarray results done by qPCR analysis demonstrated that MCF7 co-cultured with placental explants expressed reduced RNA levels of ESR1 (22% reduction, P , 0.05) and elevated levels of its targets: PGR (284% elevation), GREB1 (251% elevation, P , 0.05) and MUC1 (262% elevation, P , 0.05; see Fig. 2 ).
Taken together, the bioinformatics analyses and their validation support an active and significant effect of estrogen signaling in our research model. The published literature indicated that exposure to E 2 reduces the level of cancer cell ER receptor while increasing the level of its targets, consistent with our results. It is also well established that progesterone, which is produced by the placenta at high levels, is an E 2 antagonist. Thus, we conjectured that both E 2 and progesterone are involved in mediating the MCF7 cell phenotype modifications observed after co-culture with placenta. The microarray data validated by qPCR supported this hypothesis, with elevated levels of genes known to be up-regulated (such as KLF9, 421% elevation, P , 0.05) and decreased levels of those known to be down-regulated by progesterone (such as ESR1 and Id1, 22 and 75% reduction, respectively, P , 0.05, Fig. 2) .
The following parts of this study aimed to validate our working hypothesis. For this purpose, we analyzed the concentrations of E 2 and progesterone in co-cultures of breast cancer cells (MCF7, T47D) and placenta, and tested their effect on the MCF7 and T47D cell phenotypes.
Hormone receptor expression on MCF7 and T47D cells following their culture on 'Matrigel' with or without placental explants Our biological model is unique because cells are layered on 'Matrigel'. It is well established that MCF7 and T47D cells express ERa, PR A and PR B. However, most studies examined cells cultured on plastic. Here, we analyzed ERa, PR A and PR B expression on MCF7 and T47D cells layered on 'Matrigel' in the presence and absence of placental explants. Our previous study showed that MCF7 and T47D grown on 'Matrigel' express ERa and that placental explants reduced its expression (Tartakover-Matalon et al., 2010) . Here, a microarray validated by qPCR showed that ER mRNA levels were reduced in MCF7 cells as well. Moreover, we found that MCF7 and T47D cells grown on 'Matrigel' were positive for PR A and PR B. PR A was more prominent than PR B in MCF7 cells and the opposite was observed with T47D cells (PR A/ PR B ¼ 2.9, PR A/PR B ¼ 0.76, respectively, P , 0.05, Fig. 3A) . Microarray results demonstrated that co-culture with placenta elevated PR mRNA levels of MCF7 (see above). Nevertheless, immunoblotting showed no change in PR levels or in PR A/PR B ratio in MCF7 cells following their placental co-culture ( Fig. 3B and C) . The PR levels in T47D are higher than in MCF7 cells (Lostumbo et al., 2006) . After culturing the T47D cells with placental explants, the PR A and PR B levels were significantly reduced (55 and 88% reduction, respectively, P , 0.05), and PR A became more prominent than PR B (PR A/PR B ¼ 2.5, P , 0.05). Since the ER and PR levels can be reduced as a result of exposure to high E 2 and progesterone levels (Turgeon and Waring, 2000; Duong et al., 2007) , we further analyzed the E 2 and progesterone levels in breast cancer cells cultured with and without placental explants.
E 2 and progesterone levels in media collected from breast cancer cells and placentae cultured together or separately At 72 h, the supernatant of MCF7, T47D or placenta cultured on 'Matrigel' together or separately were collected. Low levels of E 2 were found in supernatant from MCF7 (57 pg/ml) and T47D
Figure 2 mRNA expression of E 2 and progesterone targets in MCF7 cells co-cultured with or without placental explants. MCF7 cells expressing green fluorescent protein (MCF7-eGFP) were co-cultured with placental explants on 'Matrigel' for 72 h (white bar). As a control, MCF7-eGFP were cultured separately under the same conditions (black bar). MCF7-eGFP were removed from the 'Matrigel', separated by FACS and their RNA was extracted. Messenger RNA levels of (A) the E 2 targets PGR, GREB1 and MUC1 and (B) the progesterone targets ESR1, KLF9 and Id1 were analyzed by RT-qPCR. Results were expressed as a percentage of the control value. Mean + SEM. *Significantly different from control P , 0.05, paired 't'-test (ESR1, PGR, GREB1, MUC1: n ¼ 4; Id1, KLF9: n ¼ 3).
(33 pg/ml) grown alone. T47D contained small amounts of progesterone (0.65 ng/ml), while MCF7 had none. Media from placentae grown separately contained high levels of E 2 and progesterone (705 pg/ml and 67 ng/ml, respectively). Medium collected from placental-breast cancer cell co-culture contained significantly and synergistically higher E 2 levels than those found in placentae or in cells grown separately (Fig. 3E, 1506 pg/ml and 1499 pg/ml for MCF7 and T47D, respectively, P , 0.05, q . 1). By contrast, media from placental-breast were cultured with placental explants on 'Matrigel' (white bar). As a control, MCF7-eGFP or T47D-eGFP cells were cultured separately under the same conditions (black bar). The eGFP-tagged cells were removed from the 'Matrigel', separated by cell sorter and their proteins were extracted.
Levels of PR A and B were analyzed by western blotting (n ¼ 4). (A) Ratio PR A /PR B in MCF7-eGFP and T47D-eGFP cells co-cultured with placenta (BCCL + placenta) or cultured alone (BCCL). (B) Amounts of PR A and PR B in MCF7-eGFP and T47D-eGFP cells co-cultured with placenta (BCCL + placenta) or cultured alone (BCCL). (C) Representative immunoblot of PR A and PR B levels in MCF7-eGFP and T47D-eGFP cells co-cultured with placental explants or cultured alone. (D and E) Supernatants from cultures of breast cancer cells (BCCL)
, placental explants (placenta) and placental-breast cancer cell co-cultures (BCCL + placenta) were collected and progesterone (D) and estrogen (E) concentrations were measured (MCF7: n ¼ 7, T47D: n ¼ 4, Placental explant: n ¼ 11, placental-MCF7 co-culture: n ¼ 9, placental-T47D co-culture: n ¼ 6). MCF7-black bar, T47D-white bar. (F) Placental explants were cultured in the presence of complete media (control), media without FCS (no FCS) and media without FCS and without phenol red (no phenol red and no FCS). Twenty-four hours later, media were collected and analyzed for estrogen levels by ELISA. Results were normalized to estrogen levels in control media collected from placenta cultured in the presence of complete media. Mean + SEM. *Significantly different from control P , 0.05, paired 't'-test (n ¼ 4).
# Indicates synergistic interaction between BCCL and placenta in co-culture, $ Denotes antagonistic interaction between BCCL and placenta in co-culture (see Materials and Methods for definitions).
Placental hormones and breast cancer cell migration cancer cell co-culture contained significantly less progesterone than media from placenta cultured alone (Fig. 3D , 44 ng/ml and 9 ng/ml for MCF7 and T47D, respectively, P , 0.05, q , 0.85). This demonstrates that the breast cancer cells co-cultured with placental explants are exposed to E 2 and progesterone level similar to those found in blood of normal 6-9 week pregnancies (Schindler, 2005) .
To investigate the reason for the earlier-mentioned effects of co-culture, we cultured MCF7 and T47D cells for 24 h on 'Matrigel' with placental levels of E 2 and progesterone and then measured hormone concentrations. As a control, E 2 and progesterone were added to a well coated with 'Matrigel' without any cells. We found that compared with the controls, progesterone and E 2 concentrations were decreased by the cells (MCF7: progesterone252%, E 2 215%; T47D: progesterone250%, E 2 223%, P , 0.05). Thus, the reason for progesterone reduction in placental-breast cancer cell co-culture could be progesterone consumption by the cancer cells. However, the exact cause for E 2 elevation in the co-culture remains to be resolved but is probably a consequence of breast cancer cell-placenta interaction.
FCS is needed for E 2 production by the placenta
Progesterone can be produced by first trimester placenta. However, placental estrogens are usually derived from fetal androgens, placental progestins or other steroid precursors (Boyd and Hamilton, 1970) . As placental explants were cultured without the fetus, we wished to find the E 2 precursors. We speculated that the precursors originated from either FCS or phenol red. Thus, we cultured placentae in media with and without FCS and phenol red (a weak estrogen; Welshons et al., 1988) . Placental explants cultured without FCS, and with and without phenol red produced significantly less E 2 than in full media (Fig. 3F, 81 and 86% reduction, respectively). Therefore, FCS is essential for placental E 2 production.
The elimination of breast cancer cells from the area around the EVT is mediated by E 2 and progesterone
Previously, we showed that the placenta eliminated MCF7 and T47D cells from EVT cell differentiation areas due to breast cancer cell migration away from the placenta (Tartakover-Matalon et al., 2010). Our aim was to analyze the involvement of E 2 and progesterone in mediating this effect.
The ER inhibitor (ICI 182 780) and the PR inhibitor (RU486) were added to the placental-breast cancer cell co-cultures. Areas of MCF7 and T47D elimination ('bare area') and MMP2 and MMP9 activity were assessed. After 24 h, both inhibitors reduced the 'bare area' around placental explants. Hundred nanometers RU486 produced a larger decrease than 10 nM ICI 182 780 (Fig. 4A and C, MCF7: -95 versus 235%; T47D: 271 versus 245%, P , 0.05). Both 10 and 100 nM ICI 182 780 had similar effects on the MCF7 cells but RU486 affected MCF7 in a dose-dependent manner so that 10 nM reduced the bare area by only 64%. After 72 h, both 10 nM ICI 182 780 and 100 nM RU486 still significantly decreased the 'bare area' with T47D cells (Fig. 4B, 262 and 247%, respectively, P , 0.05), whereas only RU486 was still effective for MCF7 cells (Fig. 4B, 262% , P , 0.05).
Moreover, both inhibitors decreased MMP2 and MMP9 activity in placental-MCF7 cell co-culture supernatants and again RU486 was more potent than ICI 182 780, decreases in MMP2 being 67 versus 43% and in MMP9 57 versus 40%, respectively. Effects on placental-T47D co-culture supernatants followed a similar pattern (Fig. 4D-F) .
These results support the involvement of both progesterone and E 2 , in mediating the MCF7 and T47D cell migration away from the placenta.
Placental supernatants enhance breast cancer cell motility in an ER-and PR-dependent pathway As a next step, the effect of placental supernatants containing high E 2 and progesterone concentrations on breast cancer cell migration (scratch test) and invasion (transwell assay) was tested. We found that the placental supernatants increased the MCF7 and T47D migration (Fig. 5A , B and D, +33 and +51%, respectively, P , 0.05) and invasion (Fig. 5E , F and H, +24 and +242%, respectively, P , 0.05) compared with control MCF7 and T47D supernatants. Addition of ICI 182 780 to MCF7 and T47D supernatants did not affect migration, but it decreased the MCF7 cell migration induced by placental supernatant by 33% (P , 0.05, Fig. 5A ).
RU486 did not affect MCF7 migration in the presence of MCF7 culture supernatant but inhibited T47D cell migration in the presence of T47D supernatant by 43% (Fig. 5B) . RU486 completely blocked the stimulation of migration of MCF7 cells and markedly decreased stimulation of T47D cell migration by placental supernatant (Fig. 5A and B) . Furthermore, adding RU486 to control MCF7 and T47D supernatants did not affect cell invasion; however, the addition of ICI 182 780 elevated MCF7 cell invasion (Fig. 5E ), similar to results previously obtained by Thompson et al. (1988) . The addition of either receptor inhibitor decreased the stimulation of breast cancer cell invasion caused by placental supernatant (Fig. 5E and F) .
Therefore, placental induction of motility was reversed by ER and PR inhibitors. These results indicate that soluble factors alone can induce breast cancer cell motility without placenta -breast cancer cell contact or 'Matrigel' involvement.
E 2 and progesterone in concentrations equivalent to placental culture increase breast cancer cell motility
As a final validation of the influence of E 2 and progesterone on MCF7 and T47D cell motility, breast cancer cells were cultured in the presence of either 'MCF7/T47D level' or 'placental level' of E 2 and progesterone based on the findings reported earlier. The addition of 'placental level' E 2 and progesterone to MCF7 or T47D increased their migration (Fig. 5C) and invasion (Fig. 5G) .
Taken together, we concluded that the induced motility of breast cancer cells around the placenta is a result of their exposure to elevated levels of E 2 and progesterone.
Placental supernatant activate MAPK that affects breast cancer cell migration E 2 and progesterone may activate MAP kinase (Faivre et al., 2005; Fu et al., 2008a,b; Li et al., 2010) , and this stimulation is involved in breast cancer cell migration (Li et al., 2010) . Therefore, protein levels and phosphorylation of ERK1/2, p38 and JNK were tested in MCF7 and T47D cells cultured with placental or breast cancer cell supernatant for 24 h. Placental supernatant elevated the phosphorylated forms of p38 and JNK in MCF7 and T47D cells (Fig. 6A and B ) but had no effect on ERK1/2 phosphorylation. Thus, we added p38 and JNK inhibitors (SB 202190 and SP600125, respectively) to placental and breast cancer cell supernatants and analyzed their effect on EtOH). After culture, the 'bare area' around the placental explants was measured (see Fig. 1 ). Results were expressed as a percentage of the control. *Denotes significantly different from control P , 0.05, paired 't'-test (24 h: placenta + MCF7 n ¼ 5, placenta + T47D n ¼ 7; 72 h: placenta + MCF7 n ¼ 5, placenta + T47D n ¼ 4). (C) Representative photomicrographs of breast cancer cells (MCF7 and T47D) co-cultured with placental explants in the presence of (RU486) or control. (D-F) Graphic representation and representative zymogram gel (E) of MMP2 and MMP9 activity evaluated by gelatin zymography in media collected from placental + BCCL after 24 h co-culture with ICI, RU486 or control. Mean + SEM, *Denotes significantly different from control P , 0.05, paired 't'-test. (n ¼ 4). BCCL, breast cancer cells; EVT, extravillous trophoblast; P, placental explant.
Placental hormones and breast cancer cell migration Figure 5 Placental supernatants (UF) and placental levels of E 2 +progesterone enhance breast cancer cell motility in an ER-and PR-dependent pathway. Breast cancer cell migration (A and B) and invasion (E and F) in the presence of supernatants from MCF7 or T47D (controls) or placental cultures were assayed by a scratch test and a transwell assay, respectively. Assays were done in the presence of ICI 182 780 (white bar), RU486 (gray bar) or ethanol solvent as a control (Eth, black bar). Results were expressed as a percentage of the values observed in supernatants from MCF7 or T47D cultured with Eth. Mean + SEM, *Denotes significantly different from control P , 0.05; **Indicates significant effect of ICI 182 780 or RU486 P , 0.05. Paired 't'-test (Scratch test: n ¼ 5 and n ¼ 4 for MCF7 and T47D, respectively; Transwell assay: n ¼ 4 and n ¼ 3 for MCF7 and T47D, respectively). The effect of placental concentrations of E 2 and progesterone on breast cancer cell migration was tested by a scratch test (C) and invasion by a transwell assay (G). Breast cancer cells were cultured with E 2 and progesterone concentrations equivalent to those measured in breast cancer cell (BCCL level) MCF7 and T47D cell migration. Only the JNK inhibitor blocked the stimulation of migration by placental supernatant (Fig. 6C and D) .
Thus, JNK activation is involved in the elevated migration caused by placental supernatants.
Hormones are not involved in mediating the placental effect on MCF7 cell death and elevated sub G1
Recently, we demonstrated that placental explants had no effect on T47D cell proliferation and almost no effect on their cell death (1.5% elevation; Tartakover-Matalon et al., 2010). However, placental explants increased the cell death and sub-G1 phase of the MCF7 cell cycle, yet had no effect on other cell-cycle phases (TartakoverMatalon et al., 2010) . In order to test the involvement of E 2 and progesterone in mediating the sub-G1 phase and death elevation in the co-culture system, ICI 182 780 and RU486 were added to the co-culture and the cell cycle and death were reevaluated. ICI 182 780 caused elevated cell death (+7.5%, P , 0.05, Fig. 7A ), increased sub-G1 phase (+3%, P , 0.05, Fig. 7B ) and G1 cell-cycle phase (+19%, P , 0.05, Fig. 7C ) in control cells, but had no effect on these parameters in placental-MCF7 co-cultures (Fig. 7A and C) . This is probably a result of the high E 2 levels found in the co-culture competing with the inhibitor.
The only significant effect of RU486 was the G1 phase elevation, found in MCF7 co-cultured with placenta (Fig. 7C) , suggesting that progesterone saved the cells from G1 cell-cycle arrest caused by the placenta. Once progesterone is blocked, this arrest was evident.
Further, we analyzed the effect of placental and MCF7 supernatant and of placental or MCF7 levels of E 2 and progesterone on the MCF7 cell cycle and death. Placental supernatant did not elevate the MCF7 death rates or lead to any change in the cell-cycle phases in comparison with MCF7 cultured with MCF7 supernatant (data not shown). Furthermore, no differences were observed in the cell cycle or death following culture with E 2 and progesterone in placental or MCF7 levels (24 and 72 h, Fig. 7D and E) .
We can conclude that soluble factors alone (including the combination of E 2 and progesterone) are not responsible for the increased cell death and elevated sub-G1 phases observed previously in the placental-MCF7 co-culture (Tartakover-Matalon et al., 2010) . 
ER and PR inhibitors do not reduce the EVT cell invasion
Our latest publication showed that MCF7 and T47D cell lines were most significantly affected near areas of EVT cell differentiation (Tartakover-Matalon et al., 2010) . Thus, we had to confirm that ICI 182 780 and RU486 had no adverse effects on EVT cell differentiation and thereby affect the breast cancer cells. For this purpose, placental explants layered on 'Matrigel' were exposed to ICI 182 780 and RU486. A visual assessment of EVT cell differentiation was done at 24 h. Both inhibitors had no significant effect on the EVT cell invasion compared with control placentae cultured without inhibitors. Surprisingly, increased MMP9 activity was found in the media collected from placentae cultured with ICI 182 780 versus control (50% elevation, P , 0.05). These results confirmed that the decreased breast cancer cell elimination in the presence of inhibitors was not a result of inhibited EVT cell differentiation.
Discussion
Breast cancer during pregnancy is a rare event; yet with the current trend of delaying pregnancy to a later age, its incidence is expected to increase. Some studies suggest that cancer diagnosed during pregnancy is often more aggressive than that occurring in non-pregnant women (Shousha, 2000; Woo et al., 2003; Pereg et al., 2008) . Nevertheless, there are very few reports of metastases to the products of conception. This fact suggests that the placenta is not a supportive environment for cancer cells.
This hypothesis was the basis of our previous research (TartakoverMatalon et al., 2010) . In this study, we demonstrated that placental explants induced breast cancer cell (MCF7 and T47D) elimination from sites of EVT cell invasion. This disappearance was shown to be mainly the result of migration and modest elevation in the cell death. After establishing and characterizing these phenomena, we conducted the current study to find the underlying mechanisms.
Our placental explant-breast cancer cell system is complex, involving various hormones, cytokines, growth factors and extracellular matrix (ECM) alterations. It has the advantage of being only one step away from in vivo conditions, but the complexity of this model has to be addressed. In order to deal with the numerous possibilities that exist in our system, we decided to use a non-biased microarray analysis. Microarray results suggested changes in the E 2 signaling pathway. Since most E 2 responsive genes were up-regulated while three were down-regulated, we could assume that additional factors were involved in the gene regulation. The importance of estrogen signaling to both breast cancer and pregnancy is well established (Folkerd and Dowsett, 2010) . Similarly, the interrelation and extensive crosstalk between E 2 and progesterone signaling pathways is also known (Velarde et al., 2007; Sukocheva et al., 2009) . Thus, we chose to focus on both E 2 and progesterone, and to examine their effect on the breast cancer cells in our system. First, the E 2 and progesterone concentrations were measured by ELISA. Interestingly, the E 2 concentrations were shown to be significantly increased by about 2-fold in the placental-breast cancer cell co-culture compared with the placentae cultured separately. The reason for the additional elevation in E 2 levels is unknown; however, it suggests that breast cancer cells contributed to placental E 2 production, or vice versa. Previous studies showed that E 2 can be produced locally, and its tissue concentrations may be up to 10-fold higher in breast carcinomas compared with plasma levels. This is a result of aromatase over-expression within the tumor tissue (Chetrite et al., 2000; Bulun et al., 2009; Sasano et al., 2009) , which may be expressed in both carcinoma and stromal cells (Sasano et al., 2009 ). The local production of E 2 also characterizes the placenta (Kumar et al., 2009) . Nevertheless, placental trophoblast cells lack the 17a-hydroxylase enzyme and, therefore cannot convert the C21-steroids to C19-steroids (Strauss et al., 1996) . During pregnancy, the placenta produces E 2 from the embryonic precursor. However, since our biological system did not contain the embryo, we attempted to find a source of immediate precursors of E 2 in our placental explant culture. We found that FCS was responsible for 80% of the E 2 production. We assume that the remaining 20% was derived from precursors that were in the original placental tissue; however, this needs to be confirmed. In contrast to the elevated E 2 levels, the progesterone levels decreased in breast cancer-placenta co-culture compared with those found in placenta cultured alone. Our data suggest that this reduction was a result of progesterone usage by the breast cancer cells.
We then aimed to find out whether the higher levels of E 2 and progesterone determined in our culture were responsible for the altered breast cancer cell phenotype caused by the placental explants. For this purpose, we cultured MCF7 and T47D cells with placental explants, placental supernatant and with E 2 and progesterone at the same levels found in our placental cultures ('placental level'), and compared their phenotype with that of the controls. The breast cancer cells cultured separately with or without breast cancer cell supernatant (collected previously) or with E 2 and progesterone in levels found in breast cancer cell cultures ('MCF7 and T47D level') served as controls. All experiments were done on non-starved cells, and cultured on a 'Matrigel' substrate as in the co-culture model (except for the scratch assay, which was done on a plastic). In order to further confirm the hormone-specific effect, we used the steroid-hormone receptor inhibitors ICI 182 780 and RU486, for ER and PR, respectively.
Our results consistently showed that the placenta increased MCF7 and T47D cell motility, and that progesterone and E 2 were significantly involved in mediating this effect. Furthermore, we demonstrated that JNK is specifically involved in mediating this effect.
Indeed, previous studies demonstrated that JNK facilitates E 2 induced cell migration (Li et al., 2010) . Nevertheless, as far as we know, its contribution to progesterone-derived migration had never been shown.
In our previous research, we also observed that the placenta increased MCF7 cell death. In the current study, we demonstrated that placental supernatant and the combination of placental hormones (E 2 and progesterone) did not affect MCF7 cell death, suggesting that direct contact between the MCF7 cells and the placental explants, or to placental ECM embedded factors is needed to induce MCF7 cell death.
Although E 2 and progesterone are known as mitogenic factors, no significant changes in the MCF7 cell-cycle phases were observed following their culture on 'Matrigel' with the placental explants or their supernatants.
Numerous studies have analyzed the effects of E 2 or progesterone alone on breast cancer cells. It is mostly agreed that E 2 induces breast cancer cell proliferation and cell-cycle progression. The effect of progesterone on the breast cancer cell migration and cell-cycle phases is more controversial (Clarke and Sutherland, 1990; Sumida et al., 2004; Fu et al., 2008a,b; Zheng and Lin, 2008; Dressing and Lange, 2009; Fujita et al., 2010) . The main cause for the discrepancies is different experimental methods including two-and three-dimensional systems (2D and 3D) with diverse substrates (Fu et al., 2008a,b; Lange, 2008) . Indeed, the mitogenic actions of progesterone depend on the cell polarity, a property that is not supported in 2D culture systems (Lange, 2008) . This is why Lange (2008) suggested that a system that will preserve the breast epithelial cell architecture and take into account the involvement of the ECM is needed to analyze the progesterone affect. Our established placental co-culture system that is layered on 'Matrigel' completely meets these requirements. Moreover, the existence of E 2 and progesterone in our biological model did not modify MCF7 cell-cycle phases.
Several previous observations may explain our findings. Cross talk between the two hormones and their receptors is extensive and can eventually lead to variable outcomes (Chlebowski et al., 2003; McGowan et al., 2004) . Generally, progesterone and E 2 have opposing roles in the MCF7 cell death and proliferation; thus their combined effect may cancel each other. Secondly, hormone concentrations are critical for the final result. For example, E 2 in small amounts can inhibit cell death; yet in large amounts, it can do the opposite (Lippman et al., 1976) . Finally, the fact that our experiments were done on non-starved cells layered on 'Matrigel' in the presence of variable factors may mask part of the effects that could have been observed in a 2D plastic, starved culture.
The activity of progesterone and E 2 also depends on the type of hormone receptor present (i.e. PR A, PR B, ERa, ERb forms) and the relative expression of both forms in the cell (Fu et al., 2008a,b) . MCF7 cells are known to contain only the a form of ER (Paruthiyil et al., 2004) and both forms of PR (Mullick and Katzenellenbogen, 1986) . We found that MCF7 and T47D cells cultured on 'Matrigel' contain both forms of PR. The PR A form was found to be more prominent in MCF7 cells, while the opposite was observed with T47D. After co-culturing with the placenta, both MCF7 and T47D cells showed PR A prominence. PR isoform predominance, especially PR A or an increased PR A/PR B ratio, is observed in a high proportion of breast cancers. It correlates with invasive cell behavior (Fu et al., 2008a,b) and was shown to result in aberrant progestin response, leading to loss of cell adhesion (McGowan et al., 2004) . These previous studies (McGowan et al., 2004; Fu et al., 2008a,b) support our current findings, which showed that progesterone inhibitor affected MCF7 and T47D cell motility. In the current study, progesterone inhibitor was most effective in inhibiting the placental effect on breast cancer cells. Nevertheless, although mRNA levels of PR were elevated, as expected from cells exposed to high E 2 levels (Velarde et al., 2007) , no elevated PR protein expression was found. However, as our previous studies demonstrated that like ER, which is down-regulated by E 2 (Duong et al., 2007) , PR levels are also decreased in the presence of high progesterone levels, and this effect can be independent of changes in PR mRNA (Turgeon and Waring, 2000) . Furthermore, as E 2 and progesterone levels are significantly higher in placental culture media in comparison with breast cancer cell media, the ligand-to-receptor ratio for cells co-cultured with placental explants is definitely elevated and may enhance progesterone signaling.
In conclusion, the involvement of both E 2 and progesterone in mediating breast cancer cell motility is demonstrated throughout this study, and is supported by the initial microarray experiment results. Indeed, the bioinformatics provided the evidence of E 2 pathway activation and involvement of additional factors that modulate E 2 signaling.
This increased migration contributes to the elimination of breast cancer cells from the placental area (Tartakover-Matalon et al., 2010) . In our previous study, we showed that MCF7 and T47D BCCLs were the most affected near areas of EVT cell differentiation. In the present study, we confirmed that ER and PR inhibitors did not inhibit EVT cell differentiation, suggesting a direct effect of the hormone on breast cancer cells. Since steroid hormones are soluble factors equally dispersed in the culture after 60 -70 h, elimination of the breast cancer cells specifically from EVT implantation sites suggested involvement of additional factors. The combined effect of elevated migration caused by E 2 + progesterone and cell elimination especially from EVT sites was responsible for creation of the bare areas. E 2 and progesterone hormonal concentrations in our biological model are similar to those found in pregnant women in the early weeks of pregnancy. Thus, this may imply that whereas they contribute to breast cancer cell elimination from the placenta, they may also enhance breast cancer cell invasiveness and thus disease progression during pregnancy.
